معرفی
Jack Taunton is a Professor at the University of California San Francisco (UCSF) School of Medicine, where he leads a research laboratory focused on developing chemical and biochemical tools to study cellular processes relevant to cancer and autoimmune disease. His work bridges chemistry, biochemistry, and medicine with a strong emphasis on translational research.
His educational background includes:
- B.S. in Chemistry from Trinity University (1989)
- Ph.D. in Chemistry from Harvard University (1996)
- Postdoctoral training in Cell Biology at Harvard Medical School (1996-2000)
Dr. Taunton's research spans several interconnected areas in chemical biology and drug discovery. His laboratory is particularly known for pioneering work in covalent inhibitor design, with major contributions to the development of selective kinase inhibitors including the first reversible covalent BTK inhibitors now in clinical trials. Another major research thrust involves cotransins, a family of cyclic depsipeptides that inhibit protein secretion by targeting the Sec61 translocon, representing a novel mechanism for potential cancer therapeutics. His work often combines chemical synthesis, biochemical analysis, structural biology, and cellular studies to develop tools that illuminate fundamental biological processes with therapeutic potential.
Analysis of his recent publications (2015-2023) reveals a consistent focus on chemical biology approaches to target challenging proteins, particularly through innovative covalent modification strategies. His work has evolved from early kinase inhibitor development to more sophisticated approaches targeting protein synthesis machinery (eEF1A, ribosomes) and protein secretion pathways. A unifying theme across his publications is the development of chemical probes that reveal new biological mechanisms while simultaneously establishing therapeutic potential. His research group employs a multidisciplinary approach combining synthetic chemistry, proteomics, structural biology, and cell-based assays.
His significant scientific recognitions include:
- National Science Foundation Predoctoral Fellowship (1990)
- Eli Lilly and Co. Predoctoral Fellowship Award (1993)
- Life Sciences Research Foundation Postdoctoral Fellowship (1996)
- Searle Scholar (2002)
- Alfred P. Sloan Fellow (2003)
- Brook Byers Award (2007)
- Howard Hughes Medical Institute Investigator (2010-present)
- Excellence in Teaching Award, UCSF School of Medicine (2018)
- Breakthrough Science Initiative Award from the Ono Pharma Foundation
As an HHMI Investigator since 2010, Dr. Taunton has received substantial research support to pursue high-risk, high-reward projects at the chemistry-biology interface. His laboratory has trained numerous graduate students and postdoctoral fellows who have gone on to successful careers in academia and industry. His work on reversible covalent inhibitors has led to clinical candidates, demonstrating successful translation of basic research to therapeutic applications. The laboratory maintains strong collaborations with medicinal chemists, structural biologists, and clinicians to advance their discoveries toward therapeutic applications.
Dr. Taunton's laboratory is a hub for chemical biology research at UCSF, with a particular emphasis on developing chemical tools that address previously "undruggable" targets. The lab combines expertise in synthetic chemistry, chemical proteomics, structural biology, and cell biology to develop novel therapeutic strategies. Current research directions include improving the selectivity of covalent inhibitors, developing new approaches to target protein-protein interactions, and understanding the fundamental mechanisms of protein synthesis and secretion in disease contexts.
